Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
- PMID: 33230343
- PMCID: PMC8101009
- DOI: 10.1038/s41591-020-01172-x
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
Conflict of interest statement
Competing interests
The authors declare no competing interests.
Update of
-
Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates.medRxiv [Preprint]. 2020 Aug 11:2020.08.07.20170456. doi: 10.1101/2020.08.07.20170456. medRxiv. 2020. Update in: Nat Med. 2021 Jan;27(1):4-5. doi: 10.1038/s41591-020-01172-x. PMID: 32817958 Free PMC article. Updated. Preprint.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
